Skip to main content
    E

    Entera Bio Ltd (ENTX)

    Official site

    HEALTHCARE • BIOTECHNOLOGY • NASDAQ

    $3.02
    -0.09 (-2.89%)

    Market Cap: $541.57M

    Last updated: Nov 17, 2026 at 11:04 AM ET

    Entera Bio Ltd (ENTX) Competitors

    Updated Nov 17, 2026. Similar companies are ranked by business profile, size, sector and industry; metrics come from company filings and market prices.

    The companies most similar to Entera Bio are Contineum Therapeutics, Inc. Class A Common Stock (CTNM), Enanta Pharmaceuticals (ENTA) and Regenxbio (RGNX). By market cap, Entera Bio ranks 6th of the 13 companies on this page; DBV Technologies (DBVT) is the largest at $692.19M.

    Peer Comparison

    ENTX's ROIC of -8.5% is above the peer median of -34.4%, and its revenue growth of -100.0% is below the median of 0.0%. Like the median peer, it pays no dividend.

    CompanyMarket capP/EP/SNet marginROICRev growthDiv yield
    Entera Bio (ENTX)$541.57MN/AN/A0.0%-8.5%-100.0%0.00%
    Contineum Therapeutics, Inc. Class A Common Stock (CTNM)$387.16MN/AN/A0.0%N/A0.0%0.00%
    Enanta Pharmaceuticals Inc (ENTA)$320.09MN/A4.8x-96.9%N/A-21.6%0.00%
    Regenxbio Inc (RGNX)$505.18MN/A3.1x-113.9%N/A-69.2%0.00%
    Immix Biopharma Inc (IMMX)$657.09MN/AN/A0.0%-14.9%0.0%0.00%
    Tevogen Bio Holdings Inc. (TVGN)$406.59MN/AN/A0.0%2022.8%0.0%0.00%
    Zevra Therapeutics Inc. (ZVRA)$540.30M11.6x3.7x52.8%N/A44.9%0.00%
    Prothena Corporation plc (PRTA)$419.01MN/A7.8x-45.4%N/A-74.3%0.00%
    DBV Technologies (DBVT)$692.19MN/AN/A0.0%-130.3%-42.9%0.00%
    Orchestra BioMed Holdings Inc. (OBIO)$570.61MN/A14.7x-182.5%-97.0%-89.4%0.00%
    Olema Pharmaceuticals Inc (OLMA)$662.30MN/AN/A0.0%-53.8%0.0%0.00%
    Geron Corporation (GERN)$622.98MN/A2.9x-22.0%-7.4%27.4%0.00%
    Rezolute Inc (RZLT)$353.54MN/AN/A0.0%N/A0.0%0.00%
    Peer median$522.74M11.6x4.2x0.0%-34.4%0.0%0.00%
    Market data as of Nov 17, 2026. Net margin covers the trailing 12 months, Rev growth compares the latest quarter with a year earlier and Div yield is the forward yield. P/E uses earnings per share for the last 12 months as companies report it, often adjusted, so it can show beside a negative net margin, which uses net income. P/E and P/S show N/A when those earnings or sales are negative or missing, or the multiple is above 1,000x.

    Similar Companies

    These are the 12 companies most similar to Entera Bio, ranked by how closely their business, size, sector and industry match. All 12 are in one industry, Biotechnology.

    CompanyAboutPeers
    Contineum Therapeutics, Inc. Class A Common Stock (CTNM)
    Contineum Therapeutics, Inc., a clinical stage biopharmaceutical company, focuses on discovering and developing novel oral small molecule therapies...
    CTNM competitors
    Enanta Pharmaceuticals Inc (ENTA)
    Enanta Pharmaceuticals, Inc., a biotechnology company, discovers and develops small molecule drugs for the treatment of viral infections and liver diseases.
    ENTA competitors
    Regenxbio Inc (RGNX)
    REGENXBIO Inc., a clinical-stage biotechnology company, offers candidate gene therapy products to deliver genes to cells to address genetic defects or to enable...
    RGNX competitors
    Immix Biopharma Inc (IMMX)
    Immix Biopharma, Inc., a clinical-stage biopharmaceutical company, is dedicated to the development of various tissue-specific therapies in oncology...
    IMMX competitors
    Tevogen Bio Holdings Inc. (TVGN)
    Tevogen Bio Holdings Inc. is a clinical-stage biotechnology company that develops off-the-shelf precision T cell therapeutics in virology, oncology...
    TVGN competitors
    Zevra Therapeutics Inc. (ZVRA)
    Zevra Therapeutics, Inc., a rare disease company melding science, discovers and develops various proprietary prodrugs to treat serious medical conditions...
    ZVRA competitors
    Prothena Corporation plc (PRTA)
    Prothena Corporation plc, an advanced stage clinical company, is focused on the discovery and development of new therapies for life-threatening diseases...
    PRTA competitors
    DBV Technologies (DBVT)
    DBV Technologies SA, a clinical-stage biopharmaceutical company, is dedicated to the research and development of epicutaneous immunotherapy products.
    DBVT competitors
    Orchestra BioMed Holdings Inc. (OBIO)
    Orchestra BioMed Holdings, Inc. is a therapeutic device company that develops therapeutic treatments and products for cardiovascular diseases.
    OBIO competitors
    Olema Pharmaceuticals Inc (OLMA)
    Olema Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on the discovery, development...
    OLMA competitors
    Geron Corporation (GERN)
    Geron Corporation, an advanced stage clinical biopharmaceutical company, focuses on the development and commercialization of therapies for myeloid hematologic...
    GERN competitors
    Rezolute Inc (RZLT)
    Rezolute, Inc., a clinical-stage biopharmaceutical company, develops rare and metabolic disease therapies in the United States.
    RZLT competitors

    Frequently Asked Questions About ENTX

    Who are Entera Bio's main competitors?

    The companies most similar to Entera Bio include Contineum Therapeutics, Inc. Class A Common Stock (CTNM), Enanta Pharmaceuticals (ENTA), Regenxbio (RGNX), Immix Biopharma (IMMX) and Tevogen Bio Holdings (TVGN), listed from the closest match.

    Who is Entera Bio's biggest competitor?

    DBV Technologies (DBVT) is the largest of the similar companies at $692.19M; Contineum Therapeutics, Inc. Class A Common Stock (CTNM) is the closest match by business profile, size, sector and industry.

    How does ENTX stock compare with its competitors?

    ENTX's net margin is 0.0% against a peer median of 0.0%.

    Which of Entera Bio's competitors pays a higher dividend?

    Entera Bio pays no dividend. None of the similar companies with available yields has a higher forward dividend yield.

    Is Entera Bio bigger than its competitors?

    No. Entera Bio is 6th by market cap among the 13 companies on this page; the largest is DBV Technologies (DBVT) at $692.19M.